| Sep 18 |
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
|
| Sep 18 |
Pfizer and AstraZeneca debate: when “the greater good” matters
|
| Sep 17 |
AstraZeneca PLC (AZN) Meet the Management at ESMO 2024 Conference (Transcript)
|
| Sep 17 |
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
|
| Sep 17 |
UK rollout of AZ/Oxford Covid-19 vaccine: what you need to know
|
| Sep 17 |
AstraZeneca’s Imfinzi and Imjudo found to extend survival in liver cancer trial
|
| Sep 16 |
AstraZeneca Imfinzi + Imjudo combo shows long-term liver cancer survival benefit
|
| Sep 16 |
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
|
| Sep 16 |
AstraZeneca's Trial Shows IMFINZI Reduces Risk of Recurrence, Death in Patients With Bladder Cancer
|
| Sep 16 |
ASCO 2020: ADAURA trial demonstrates a 79% reduction in the risk of death with Tagrisso in the adjuvant setting
|
